NCT00316693View on ClinicalTrials.gov

Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

1,046

Participants

Timeline

Start Date

April 26, 2006

Primary Completion Date

February 10, 2009

Study Completion Date

February 10, 2009

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

HPV-16/18 vaccine (Cervarix™)

Intramuscular injection, 3 doses

BIOLOGICAL

Aimmugen™

Intramuscular injection, 3 doses

Trial Locations (4)

892-0824

GSK Investigational Site, Kagoshima

160-0017

GSK Investigational Site, Tokyo

183-0056

GSK Investigational Site, Tokyo

Unknown

GSK Investigational Site

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY